On the other hand, homozygote MTHFR mutation with the subsequent hyperhomocysteinemia is found in around 10% of the general population [1] but has a controversial role in the development of VTE [33], and thus, related to the growing evidence of its minimal clinical utility, testing for MTHFR polymorphism is currently not recommended routinely [34]. The gene discussed is MTHFR; the disease is hyperhomocysteinemia.